Sharemaestro company-news research for LENSAR Inc (LNSR), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest LNSR news and sentiment
LENSAR Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone72/100
→
Published 30-day score53/100
Latest source headline
LENSAR stock highlights 18 percent Q2 revenue growth
AD HOC NEWS · 07 Oct 2026 00:50
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
6 current stories are mapped specifically to LNSR.
The score uses 5 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.141.
Confidence is 22/100, below the threshold for a firm score.
53/100
News scoreEarly balanced news score
22/100
Confidencethin evidence
92%/100
Company news6 company stories
94/100
Story agreement6/100 difference
News history
Daily score and story count over 30 days
14 Sep29 Sep13 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence3
0.141 after freshness weightingSource breadth100
5 independent publishersCompany relevance92
share tied directly to this companyFreshness20
recency-weighted evidenceAgreement94
how closely stories agreePublisher mix57
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks25 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202654USD 6.37-5.6%
02 Oct 202655USD 6.75-2.5%
25 Sep 202650USD 6.92-2.1%
18 Sep 202650USD 7.07-7.0%
11 Sep 202652USD 7.6-11.4%
04 Sep 202654USD 8.58+3.4%
28 Aug 202659USD 8.3-4.4%
21 Aug 202665USD 8.68+5.9%
Provisional evidence
News subjects
What is shaping the score
Earnings665 stories · 83%
Market update501 stories · 17%
Source mix
Where the evidence comes from
AD HOC NEWS623 stories · 50%
Investing.com801 stories · 17%
Stock Traders Daily501 stories · 17%
The Globe and Mail501 stories · 17%
Recurring subjects
Subjects appearing most often
Financial Markets6Life Sciences5Earnings5Mergers And Acquisitions1Finance1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
08 May50 neutral12 Oct 08:46
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 12 Oct 08:46 | 53 | -3 | 23/100 (-7) | 6 (0) | Provisional |
| 07 Oct 23:59 | 56 | +3 | 30/100 (+10) | 6 (+1) | Provisional |
| 06 Oct 23:59 | 53 | -1 | 20/100 (-3) | 5 (+1) | Provisional |
| 04 Oct 23:59 | 54 | -2 | 23/100 (-6) | 4 (0) | Provisional |
| 30 Sep 23:59 | 56 | +0 | 29/100 (-2) | 4 (+1) | Provisional |
| 29 Sep 23:59 | 56 | +6 | 31/100 (+17) | 3 (-2) | Provisional |
| 22 Sep 23:59 | 50 | -6 | 14/100 (-7) | 5 (-34) | Provisional |
| 02 Sep 23:59 | 56 | -2 | 21/100 (-5) | 39 (-4) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 6 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings2 stories
0.0%100.0%
Each side uses the same scale: 0–100.0% of the retained directional evidence.
Where the influence comes from
63.3%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
67/100 tone
LENSAR (LNSR) reported a strong second quarter in 2026, with revenue increasing by 18% year-over-year to $16.5 million, largely driven by a 20% rise in recurring revenue. The cataract-surgery technology company also surpassed analyst expectations, posting adjusted earnings of $0.10 per sh…
63.3% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
LENSAR (LNSR) reported a strong second quarter in 2026, with revenue increasing by 18% year-over-year to $16.5 million, largely driven by a 20% rise in recurring revenue. The cataract-surgery technology company also surpassed analyst expectations, posting adjusted earnings of $0.10 per share against a predicted loss. Despite a recent rating cut from Buy to Hold by Wall Street Zen, the company maintained a Hold consensus with analysts, with its market capitalization standing at $82.3 million.
- Published
- 07 Oct 2026 00:50
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 53/100
- 30-day weight
- 63.3% of directional evidence · 6.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
(LNSR) Movement Within Algorithmic Entry Frameworks
Lensar Inc. (NASDAQ: LNSR) is showing weak sentiment across all horizons, supporting a short bias according to AI models. The analysis identifies a mid-channel oscillation pattern and an exceptional 112.5:1 risk-reward short setup targeting a 29.4% downside. Three distinct trading strateg…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Lensar Inc. (NASDAQ: LNSR) is showing weak sentiment across all horizons, supporting a short bias according to AI models. The analysis identifies a mid-channel oscillation pattern and an exceptional 112.5:1 risk-reward short setup targeting a 29.4% downside. Three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) have been generated with specific entry, target, and stop-loss zones.
- Published
- 06 Oct 2026 19:36
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial Markets
—Unscored
EarningsNot used in direction
LENSAR stock gained 2.74 percent as analysts weigh growth strategically
LENSAR (LNSR) stock gained 2.74% on Nasdaq, reaching USD 6.75 on October 2, 2026, driven by an 18% increase in Q2 2026 revenue to USD 16.5 million. The company also saw significant improvements in GAAP net income and adjusted EBITDA, with recurring revenue making up 83% of quarterly sales…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
LENSAR (LNSR) stock gained 2.74% on Nasdaq, reaching USD 6.75 on October 2, 2026, driven by an 18% increase in Q2 2026 revenue to USD 16.5 million. The company also saw significant improvements in GAAP net income and adjusted EBITDA, with recurring revenue making up 83% of quarterly sales. Analysts currently hold a consensus "Hold" rating with an average price target of USD 11.33.
- Published
- 04 Oct 2026 18:03
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
Lensar Inc (LNSR-Q) Stock Price and News
This article provides stock price information and news updates for Lensar Inc. (LNSR-Q), a medical device company specializing in femtosecond laser systems for cataract treatment. It includes market data, recent news headlines detailing analyst ratings, earnings calls, and company announc…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides stock price information and news updates for Lensar Inc. (LNSR-Q), a medical device company specializing in femtosecond laser systems for cataract treatment. It includes market data, recent news headlines detailing analyst ratings, earnings calls, and company announcements, and a brief company profile.
- Published
- 30 Sep 2026 00:57
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
80/100 tone
Lucid Capital Markets has initiated coverage on LENSAR Inc. (NASDAQ:LNSR) with a Buy rating and a price target of $11.00, indicating significant upside potential from its current trading price of $6.92. The firm believes LENSAR is undervalued and is monitoring the rebuild of its commercia…
36.7% of directional evidence
High story strength
Scoring detailsDirect company coverage
Lucid Capital Markets has initiated coverage on LENSAR Inc. (NASDAQ:LNSR) with a Buy rating and a price target of $11.00, indicating significant upside potential from its current trading price of $6.92. The firm believes LENSAR is undervalued and is monitoring the rebuild of its commercial organization, aiming for a return to higher placement rates. Recent Q2 2026 financial results showed LENSAR surpassed earnings and revenue expectations, demonstrating growth in recurring revenue and profitability.
- Published
- 29 Sep 2026 00:57
- News subject
- Earnings
- Why this score
- Analyst upgrade, Beat expectations, Buy Rating, Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- High · 60/100
- 30-day weight
- 36.7% of directional evidence · 14.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 4 consolidated
EarningsFinanceFinancial MarketsLife SciencesMergers And Acquisitions
—Unscored
EarningsNot used in direction
LENSAR stock holds near its latest reported level
LENSAR stock is trading near its latest reported level in September 2026, with its valuation dependent on recent company figures and operating milestones. The article emphasizes that medical technology remains central to LENSAR's business, and investors should focus on measurable operatin…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
LENSAR stock is trading near its latest reported level in September 2026, with its valuation dependent on recent company figures and operating milestones. The article emphasizes that medical technology remains central to LENSAR's business, and investors should focus on measurable operating progress like revenue, gross margin, cash generation, and the installed base rather than standalone share-price snapshots. It also clarifies the distinction between reporting and publication dates and the importance of dated market data for accurate assessment.
- Published
- 22 Sep 2026 07:09
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
Earlier company news
LNSR news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
02Sep 2026
ArchivedNeutral tone
LENSAR Inc (LNSR) Stock News Today
Article detailsHistorical record
- Published
- 2 Sep 2026 12:55
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
29Aug 2026
Article detailsHistorical record
- Published
- 29 Aug 2026 18:20
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 1 consolidated
29Aug 2026
Article detailsHistorical record
- Published
- 29 Aug 2026 08:00
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 1 consolidated
25Aug 2026
ArchivedNeutral tone
Lensar Inc Earnings Call Highlights Growth Momentum
Article detailsHistorical record
- Published
- 25 Aug 2026 01:36
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
24Aug 2026
ArchivedNeutral tone
Lensar Inc Earnings Call Highlights Growth Momentum
Article detailsHistorical record
- Published
- 24 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
20Aug 2026
ArchivedNeutral tone
LENSAR (LNSR) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, August 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Nicholas Curtis Interim Chief Financial Officer - Michael Rossi Investor Relations Adviser - Lee Roth Full Conference Call Transcript Operator: Hello, and welcome to L…
Article detailsHistorical record
Image source: The Motley Fool. DATE Thursday, August 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Nicholas Curtis Interim Chief Financial Officer - Michael Rossi Investor Relations Adviser - Lee Roth Full Conference Call Transcript Operator: Hello, and welcome to LENSAR, Inc. Second Quarter 2026 Results Conference Call. [Operator Instructions] I would now like to turn the call over to Lee Roth, President of Burns McClellan, Investor Relations Adviser to LENSAR. Mr. Roth, please go ahead. Lee Roth: Thanks, Towanda. Good morning, everyone, and once again, welcome to the L
- Published
- 20 Aug 2026 15:13
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Balance SheetEarningsFinancial ResultsFinancialsFourth QuarterHealthcare
20Aug 2026
ArchivedPositive tone
LNSR Maintains Buy Rating by BTIG -- Price Target Raised to $10.
BTIG has maintained a Buy rating for LENSAR (LNSR) and increased its price target from $9.00 to $10.00, reflecting confidence in the company's growth potential within the medical devices sector. Despite this positive analyst outlook, LENSAR is considered significantly overvalued with a GF…
Article detailsHistorical record
BTIG has maintained a Buy rating for LENSAR (LNSR) and increased its price target from $9.00 to $10.00, reflecting confidence in the company's growth potential within the medical devices sector. Despite this positive analyst outlook, LENSAR is considered significantly overvalued with a GF Value™ of $4.91 compared to its current price of $8.72, and its low profitability rank raises concerns for investors. Gurus are adding positions, suggesting some positive sentiment, but caution is advised due to the valuation and unprofitability.
- Published
- 20 Aug 2026 11:41
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 2 consolidated
EarningsFinanceFinancial MarketsLife Sciences
19Aug 2026
ArchivedNegative tone
LNSR|LENSAR Inc|Price:8.440|Chg%:-0.280
Article detailsHistorical record
- Published
- 19 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
17Aug 2026
Article detailsHistorical record
- Published
- 17 Aug 2026 20:38
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
17Aug 2026
ArchivedPositive tone
Earnings To Watch: LENSAR Inc (LNSR) Q2 2026 -- GF Value Sees 13% Upside
LENSAR Inc (LNSR) is scheduled to release its Q2 2026 earnings on August 13, 2026, with revenue expected at $14.65 million and an earnings per share of -$0.17. While revenue and earnings estimates for 2026 and 2027 have remained flat over the past 90 days, the company's stock shows a "Buy…
Article detailsHistorical record
LENSAR Inc (LNSR) is scheduled to release its Q2 2026 earnings on August 13, 2026, with revenue expected at $14.65 million and an earnings per share of -$0.17. While revenue and earnings estimates for 2026 and 2027 have remained flat over the past 90 days, the company's stock shows a "Buy" status from analysts. GuruFocus's GF Value suggests a 12.99% upside from its current price of $6.08, despite missing revenue and earnings expectations in the previous quarter.
- Published
- 17 Aug 2026 03:45
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial Markets
16Aug 2026
ArchivedNegative tone
LNSR Looks 65.7% Overvalued on GF Value™
LENSAR Inc (LNSR) is set to discuss strategic updates at a virtual meeting on August 20, 2026. Despite a high Price-to-Sales ratio (2.0x) and being unprofitable, two prominent gurus have added to their positions. GuruFocus’ GF Value™ indicates LNSR is 65.7% overvalued, yet its GF Score™ o…
Article detailsHistorical record
LENSAR Inc (LNSR) is set to discuss strategic updates at a virtual meeting on August 20, 2026. Despite a high Price-to-Sales ratio (2.0x) and being unprofitable, two prominent gurus have added to their positions. GuruFocus’ GF Value™ indicates LNSR is 65.7% overvalued, yet its GF Score™ of 67/100 reflects strong growth potential despite profitability and valuation concerns.
- Published
- 16 Aug 2026 14:49
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
16Aug 2026
Article detailsHistorical record
- Published
- 16 Aug 2026 00:42
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
15Aug 2026
ArchivedPositive tone
LENSAR (NASDAQ:LNSR) Upgraded at Wall Street Zen
Wall Street Zen upgraded LENSAR (NASDAQ:LNSR) from "sell" to "hold," aligning with the overall analyst consensus of "Hold" and an $11.00 price target. This upgrade follows LENSAR's positive quarterly earnings, which surpassed revenue and EPS expectations. The company also saw increased in…
Article detailsHistorical record
Wall Street Zen upgraded LENSAR (NASDAQ:LNSR) from "sell" to "hold," aligning with the overall analyst consensus of "Hold" and an $11.00 price target. This upgrade follows LENSAR's positive quarterly earnings, which surpassed revenue and EPS expectations. The company also saw increased institutional investment and continued demand for its ALLY systems.
- Published
- 15 Aug 2026 08:43
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
15Aug 2026
Article detailsHistorical record
- Published
- 15 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
14Aug 2026
LENSAR (LNSR) recently reported its best-ever quarter for profitability, driven by high-margin recurring procedure revenue in its cataract surgery platform. Despite this, investors showed a muted reaction, with the stock slightly slipping, as questions remain about the durability of these…
Article detailsHistorical record
LENSAR (LNSR) recently reported its best-ever quarter for profitability, driven by high-margin recurring procedure revenue in its cataract surgery platform. Despite this, investors showed a muted reaction, with the stock slightly slipping, as questions remain about the durability of these margin gains, especially given a significant tariff refund. The company's future growth hinges on increasing ALLY system utilization and expanding its international presence to solidify its recurring revenue model.
- Published
- 14 Aug 2026 23:53
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
14Aug 2026
LENSAR (LNSR) recently reported its best-ever quarter for profitability, driven by high-margin recurring procedure revenue in its cataract surgery platform. Despite this, investors showed a muted reaction, with the stock slightly slipping, as questions remain about the durability of these…
Article detailsHistorical record
LENSAR (LNSR) recently reported its best-ever quarter for profitability, driven by high-margin recurring procedure revenue in its cataract surgery platform. Despite this, investors showed a muted reaction, with the stock slightly slipping, as questions remain about the durability of these margin gains, especially given a significant tariff refund. The company's future growth hinges on increasing ALLY system utilization and expanding its international presence to solidify its recurring revenue model.
- Published
- 14 Aug 2026 18:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
14Aug 2026
ArchivedPositive tone
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
LENSAR, Inc. announced strong financial results for Q2 2026, including an 18% increase in total revenue and a 20% rise in recurring revenue compared to Q2 2025. The company placed 10 ALLY Robotic Cataract Laser Systems, bringing the total installed base to 215, and reported positive net i…
Article detailsHistorical record
LENSAR, Inc. announced strong financial results for Q2 2026, including an 18% increase in total revenue and a 20% rise in recurring revenue compared to Q2 2025. The company placed 10 ALLY Robotic Cataract Laser Systems, bringing the total installed base to 215, and reported positive net income and its strongest Adjusted EBITDA to date. These results reflect growing utilization and sustained demand for their ALLY System, reinforcing confidence in their recurring revenue model and future growth trajectory.
- Published
- 14 Aug 2026 11:43
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
EarningsLife Sciences
14Aug 2026
LENSAR (LNSR) recently reported its best-ever quarter for profitability, driven by high-margin recurring procedure revenue in its cataract surgery platform. Despite this, investors showed a muted reaction, with the stock slightly slipping, as questions remain about the durability of these…
Article detailsHistorical record
LENSAR (LNSR) recently reported its best-ever quarter for profitability, driven by high-margin recurring procedure revenue in its cataract surgery platform. Despite this, investors showed a muted reaction, with the stock slightly slipping, as questions remain about the durability of these margin gains, especially given a significant tariff refund. The company's future growth hinges on increasing ALLY system utilization and expanding its international presence to solidify its recurring revenue model.
- Published
- 14 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
14Aug 2026
ArchivedNegative tone
LNSR|LENSAR Inc|Price:8.440|Chg%:-0.280
Article detailsHistorical record
- Published
- 14 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
14Aug 2026
ArchivedNegative tone
LNSR|LENSAR Inc|Price:8.200|Chg%:-0.070
Article detailsHistorical record
- Published
- 14 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
14Aug 2026
ArchivedPositive tone
Lensar Returns to Profit in Q2 on Strong Demand for ALLY Cataract System
Lensar, Inc. reported strong financial results for Q2 2026, returning to profit with $3.5 million in net income, up from a loss the previous year. The company saw an 18% increase in revenue to $16.5 million, driven by demand for its ALLY Robotic Cataract Laser System, with 10 new systems …
Article detailsHistorical record
Lensar, Inc. reported strong financial results for Q2 2026, returning to profit with $3.5 million in net income, up from a loss the previous year. The company saw an 18% increase in revenue to $16.5 million, driven by demand for its ALLY Robotic Cataract Laser System, with 10 new systems placed and a backlog of 13. Lensar attributes its success to its business model, increasing utilization, and overcoming the uncertainty of a terminated merger with Alcon.
- Published
- 14 Aug 2026 05:40
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife SciencesMergers And AcquisitionsTechnology
14Aug 2026
LENSAR (LNSR) reported strong Q2 2026 results, with an 18% revenue growth and a return to profitability after its terminated merger with Alcon. The company saw significant increases in recurring revenue, procedure volume, and expanded its installed base of ALLY robotic laser cataract syst…
Article detailsHistorical record
LENSAR (LNSR) reported strong Q2 2026 results, with an 18% revenue growth and a return to profitability after its terminated merger with Alcon. The company saw significant increases in recurring revenue, procedure volume, and expanded its installed base of ALLY robotic laser cataract systems. LENSAR is now focusing on increasing ALLY system adoption, utilization, and reestablishing international distributor relationships to drive long-term growth.
- Published
- 14 Aug 2026 00:07
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 4 consolidated
Cataract SurgeryEarningsFinanceGross MarginHealthcareInternational Expansion
13Aug 2026
ArchivedPositive tone
LENSAR Q2 Earnings Call Highlights
LENSAR (LNSR) reported strong Q2 2026 results, with an 18% revenue growth and a return to profitability after its terminated merger with Alcon. The company saw significant increases in recurring revenue, procedure volume, and expanded its installed base of ALLY robotic laser cataract syst…
Article detailsHistorical record
LENSAR (LNSR) reported strong Q2 2026 results, with an 18% revenue growth and a return to profitability after its terminated merger with Alcon. The company saw significant increases in recurring revenue, procedure volume, and expanded its installed base of ALLY robotic laser cataract systems. LENSAR is now focusing on increasing ALLY system adoption, utilization, and reestablishing international distributor relationships to drive long-term growth.
- Published
- 13 Aug 2026 21:41
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Cataract SurgeryEarningsFinanceHealthcareLife SciencesMedical Technology
13Aug 2026
ArchivedPositive tone
LENSAR (LNSR) swings to profit on $39.9M H1 net income and $10M merger fee
Article detailsHistorical record
- Published
- 13 Aug 2026 21:32
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
13Aug 2026
ArchivedNegative tone
LNSR Looks 44.6% Overvalued on GF Value™
LENSAR Inc (LNSR) is set to discuss strategic updates at a virtual meeting on August 20, 2026. Despite a high Price-to-Sales ratio (2.0x) and being unprofitable, two prominent gurus have added to their positions. GuruFocus’ GF Value™ indicates LNSR is 65.7% overvalued, yet its GF Score™ o…
Article detailsHistorical record
LENSAR Inc (LNSR) is set to discuss strategic updates at a virtual meeting on August 20, 2026. Despite a high Price-to-Sales ratio (2.0x) and being unprofitable, two prominent gurus have added to their positions. GuruFocus’ GF Value™ indicates LNSR is 65.7% overvalued, yet its GF Score™ of 67/100 reflects strong growth potential despite profitability and valuation concerns.
- Published
- 13 Aug 2026 21:02
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
EarningsFinanceFinancial MarketsLife Sciences
13Aug 2026
Article detailsHistorical record
- Published
- 13 Aug 2026 20:46
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
13Aug 2026
ArchivedPositive tone
LENSAR (NASDAQ:LNSR) Posts Quarterly Earnings Results, Beats Expectations By $0.26 EPS
LENSAR (NASDAQ:LNSR) announced strong quarterly earnings, reporting $0.10 EPS, significantly beating analyst expectations of a ($0.16) loss. The company saw an 18% year-over-year revenue increase to $16.5 million, driven by growth in recurring and procedure revenues, and achieved a record…
Article detailsHistorical record
LENSAR (NASDAQ:LNSR) announced strong quarterly earnings, reporting $0.10 EPS, significantly beating analyst expectations of a ($0.16) loss. The company saw an 18% year-over-year revenue increase to $16.5 million, driven by growth in recurring and procedure revenues, and achieved a record adjusted EBITDA of $3.6 million. Despite these positive results and a 27.9% stock increase, the company noted a decline in cash to $13.6 million and anticipates higher operating expenses and seasonal weaknesses in Q3.
- Published
- 13 Aug 2026 18:50
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
13Aug 2026
ArchivedPositive tone
LENSAR (NASDAQ:LNSR) Posts Quarterly Earnings Results, Beats Expectations By $0.26 EPS
LENSAR (NASDAQ:LNSR) announced strong quarterly earnings, reporting $0.10 EPS, significantly beating analyst expectations of a ($0.16) loss. The company saw an 18% year-over-year revenue increase to $16.5 million, driven by growth in recurring and procedure revenues, and achieved a record…
Article detailsHistorical record
LENSAR (NASDAQ:LNSR) announced strong quarterly earnings, reporting $0.10 EPS, significantly beating analyst expectations of a ($0.16) loss. The company saw an 18% year-over-year revenue increase to $16.5 million, driven by growth in recurring and procedure revenues, and achieved a record adjusted EBITDA of $3.6 million. Despite these positive results and a 27.9% stock increase, the company noted a decline in cash to $13.6 million and anticipates higher operating expenses and seasonal weaknesses in Q3.
- Published
- 13 Aug 2026 18:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
13Aug 2026
ArchivedPositive tone
LENSAR Q2 Earnings Call Highlights
LENSAR reported strong second-quarter 2026 results with 18% revenue growth, driven by increasing adoption of its ALLY robotic laser cataract system. The company achieved its strongest quarterly adjusted EBITDA to date and saw significant increases in procedures and U.S. market share. LENS…
Article detailsHistorical record
LENSAR reported strong second-quarter 2026 results with 18% revenue growth, driven by increasing adoption of its ALLY robotic laser cataract system. The company achieved its strongest quarterly adjusted EBITDA to date and saw significant increases in procedures and U.S. market share. LENSAR is focused on expanding its installed base, increasing system utilization, and growing recurring revenue, while also planning international expansion efforts.
- Published
- 13 Aug 2026 17:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Cataract SurgeryEarningsFinanceHealthcareLife SciencesMedical Technology
13Aug 2026
ArchivedPositive tone
Earnings call transcript: LENSAR beats on Q2 2026 profit, shares jump premarket
LENSAR Inc. reported strong Q2 2026 results, with adjusted earnings of $0.10 per share and revenue of $16.5 million, significantly beating analyst expectations. The company's stock jumped 16.85% premarket due to increased recurring revenue, procedure volume, and improved profitability, in…
Article detailsHistorical record
LENSAR Inc. reported strong Q2 2026 results, with adjusted earnings of $0.10 per share and revenue of $16.5 million, significantly beating analyst expectations. The company's stock jumped 16.85% premarket due to increased recurring revenue, procedure volume, and improved profitability, including a record adjusted EBITDA of $3.6 million. Management highlighted the successful re-emergence as an independent business post-merger termination and outlined a strategy focused on expanding the ALLY system's installed base, increasing utilization, and growing recurring revenue, while also addressing anticipated seasonal weakness in Q3 and ongoing international distributor rebuilding efforts.
- Published
- 13 Aug 2026 14:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 8 consolidated
Cataract SurgeryEarningsFinanceGross MarginHealthcareInternational Expansion
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to LNSR, but the headline and available text are not mainly about LENSAR Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of LNSR sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.